Staff

Schloer S, Hennesen J, Rueschpler L, Zamzamy M, Flomm F, Ip WH, Pirosu A, Dobner T, Altfeld M (2025). The host cell factor DDX3 mediates sex dimorphism in the IFNα response of plasmacytoid dendritic cells upon TLR activation. Pharmacol Res. 2025 May 10; PubMed

Mensching L, Beiersdorfer M, Schloer S, Köllmann S, Reinsberg F, Padoan B, Fittje P, Trenkner T, Zaayenga A, Martrus G, Almahfoud M, Stürzel CM, Sauter D, Kirchhoff F, Schulze Zur Wiesch J, Altfeld M, Garcia-Beltran WF, Hoelzemer A (2025). HIV-1 infection of macrophages differentially primes NK-cell cytotoxicity and proinflammatory cytokine production. iScience. 28/2025; PubMed

Rueschpler L, Schloer S (2025). Beyond the surface: P2Y receptor downstream pathways, TLR crosstalk and therapeutic implications for infection and autoimmunity. Pharmacol Res. 219/2025; PubMed

Schloer S, Hennesen J, Rueschpler L, Zamzamy M, Flomm F, Skenteris NT, Ip WH, Pirosu A, Dobner T, Altfeld M (2025). Corrigendum to "The host cell factor DDX3 mediates sex dimorphism in the IFNα response of plasmacytoid dendritic cells upon TLR activation" [Pharmacol. Res. 216(June) (2025) 107764]. Pharmacol Res. 2025 Aug 01; PubMed

Zamzamy M, Post S, Ip WH, Hahlin E, Kühn S, Pirosu A, Conze C, Baumdick M, Bunders MJ, Zecher BF, Hoelzemer A, Linder S, Arnberg N, Dobner T, Altfeld M, Schloer S (2025). Synergistic antiviral activity against human adenovirus through combination of itraconazole and brincidofovir. Br J Pharmacol. 2025 Nov 28; PubMed

Post S, Rueschpler L, Schloer S (2025). Endolysosomes as a sorting hub for emerging viruses: Gatekeepers of cellular defense, viral fate and promising therapeutic target. Pharmacol Res. 222/2025; PubMed

Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller LM, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer MH, Poch T, Sebode M, , Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer KJ, Schumacher U, Sauter G, Carrington M, Franke A, Bunders MJ, Schramm C, Altfeld M (2024). HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells. Gut. 73/2024; PubMed

Kroll MK, Schloer S, Candan P, Korthals N, Wenzel C, Ihle H, Gilhaus K, Liedtke KR, Schöfbänker M, Surmann B, Schröter R, Neugebauer U, Mall G, Oswald S, Ludwig S, Rescher U, Vollenbröker B, Ciarimboli G (2023). Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. Biomolecules. 13/2023; PubMed

Baumdick ME, Niehrs A, Degenhardt F, Schwerk M, Hinrichs O, Jordan-Paiz A, Padoan B, Wegner LHM, Schloer S, Zecher BF, Malsy J, Joshi VR, Illig C, Schröder-Schwarz J, Möller KJ, , Martin MP, Yuki Y, Ozawa M, Sauter J, Schmidt AH, Perez D, Giannou AD, Carrington M, Davis RS, Schumacher U, Sauter G, Huber S, Puelles VG, Melling N, Franke A, , Altfeld M, Bunders MJ (2023). HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis. Gastroenterology. 165/2023; PubMed

Faist A, Schloer S, Mecate-Zambrano A, Janowski J, Schreiber A, Boergeling Y, Conrad BCG, Kumar S, Toebben L, Schughart K, Baumgardt M, Kessler M, Hoenzke K, Hocke A, Trautmann M, Hartmann W, Kato H, Rescher U, Christersson A, Kuehn J, Mellmann A, Wolff T, Kuempers P, Rovas A, Wiewrodt R, Wiebe K, Barth P, Ludwig S, Brunotte L (2022). Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. Antiviral Res. 209/2023; PubMed

Braun SA, Bauer AT, Németh C, Rózsa A, Rusch L, Erpenbeck L, Schloer S, Silling S, Metze D, Gerber PA, Schneider SW, Gyulai R, Homey B (2022). Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts. Int J Mol Sci. 23/2022; PubMed

Schreiber A, Ambrosy B, Planz O, Schloer S, Rescher U, Ludwig S (2022). The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. Pharmaceutics. 14/2022; PubMed

Schloer S, Treuherz D, Faist A, de Witt M, Wunderlich K, Wiewrodt R, Wiebe K, Barth P, Wälzlein JH, Kummer S, Balkema-Buschmann A, Ludwig S, Brunotte L, Rescher U (2022). 3D Ex vivo tissue platforms to investigate the early phases of influenza a virus- and SARS-CoV-2-induced respiratory diseases. Emerg Microbes Infect. 11/2022; PubMed

Schloer S, Goretzko J, Rescher U (2022). Repurposing Antifungals for Host-Directed Antiviral Therapy? Pharmaceuticals (Basel). 15/2022; PubMed